As reported in The Lancet by Christopher C. Parker, MD, of Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, and colleagues, initial findings in the phase III RADICALS-RT trial
On November 9, the U.S. Food and Drug Administration (FDA) approved FoundationOne Liquid CDx to be used as a companion diagnostic for olaparib. As a companion diagnostic, FoundationOne Liquid CDx will use a blood-based biopsy to identify patients with BRCA1, BRCA2, and/or ATM alterations and metastatic castration-resistant prostate cancer who may be appropriate for treatment with olaparib.
A study by Liu et al published in Molecular Cancer Research investigated why Black men appear to be more likely to develop aggressive prostate cancer than White men. Researchers found that prostate tumors in Black men had higher frequencies of distinct genetic alterations, which may contribute to more aggressive disease and a higher mortality rate.
As reported in JAMA Oncology, Dess et al have developed a novel clinical prognostic stage group system for nonmetastatic prostate cancer that "meets criteria set forth by the American Joint Committee on Cancer [AJCC] Precision Medicine Core committee… [and outperforms] the existing [AJCC] system and commonly used risk-stratification systems."
The addition of the radiotracer fluciclovine to positron-emission tomography (PET) imaging for treatment planning led to superior failure-free survival compared with conventional imaging in men with prostate cancer who had undergone radical prostatectomy and were experiencing biologic recurrence of their cancer, according to the first results of a phase III trial presented at the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting, which is being held virtually.